Pancreatic Cancer

Ghaneh, Paula; and, Conor Magee; Neoptolemos, John P.

doi:10.1002/9780470987360.ch25

Cited by 5 publications

(16 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CA19-9 is the most commonly used marker for pancreatic cancer. It has a sensitivity of 70%-90% and specificity of 90% [28] . CA19-9 is the only biomarker with demonstrated clinical usefulness and is particularly useful for assessing response and identifying early recurrence after treatment in patients with known pancreatic cancer [29][30][31][32][33] .…”

Section: Discussionmentioning

confidence: 99%

Combination of recombinant adenovirus-p53 with radiochemotherapy in unresectable pancreatic carcinoma

Cai

Zhang

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: To assess the safety and efficacy of the combination of recombinant adenovirus-p53 (rAd-p53) with radiochemotherapy for treating unresectable pancreatic carcinoma.Methods: The eligible patients received concurrent rAd-p53 intratumoral injection and radiochemotherapy. Intratumoral injection of rAd-p53 was guided by B ultrasound. Radiochemotherapy consisted of intensity-modulated radiotherapy (IMRT) at two dose levels and intravenous gemcitabine (Gem). For radiotherapy, gross target volume (GTV) and clinical target volume (CTV) were 55-60 Gy and 45-55 Gy in 25-30 fractions, respectively. Concurrent intravenous gemcitabine was administered at 350 mg/m 2 , weekly, for 6 weeks. The primary end points included toxicity, clinical benefit response (CBR) and disease control rate (DCR). The secondary end points included progression-free survival (PFS) and overall survival (OS).Results: Fifteen eligible patients were enrolled. Eight patients (53.3%) were evaluated as CBR and 12 (80%) achieved DCR. The median PFS and OS were 6.7 and 13.8 months, respectively. One-year PFS and OS were 40.0% and 51.1%, respectively. There were 8 (53.3%) patients reported grade 3 toxicities including neutropenia (6 patients, 40%), fever (1 patient, 6.7%) and fatigue (1 patient, 6.7%). There was no grade 4 toxicity reported.Conclusion: Combination of rAd-p53 in unresectable pancreatic carcinoma showed encouraging efficacious benefit and was well tolerated. Long-term follow-up is needed to confirm the improvement of PFS and OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of recombinant adenovirus-p53 with radiochemotherapy in unresectable pancreatic carcinoma

Cai

Zhang

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Im Vergleich zur Monotherapie mit 5-FU war jedoch eine Steigerung der Toxizität ohne zusätzli-che Verbesserung des Überlebens vorhanden [17]. Gemcitabine gehört zu einer Reihe neuerer Zytotoxika, die bei Pankreaskarzinom getestet werden [24,64]. Es besteht auch weiterhin ein kontinuierliches Interesse an Fluoropyrimidine innerhalb von Studien, in denen die Effektivität von 5-FU nach venöser Applikation und durch Entwicklung oral zu verabreichender Chemotherapeutika verbessert werden soll [24,64] [39].…”

Section: Onkologische Therapien Beim Fortgeschrittenen Pankreaskarzinomunclassified

“…Gemcitabine gehört zu einer Reihe neuerer Zytotoxika, die bei Pankreaskarzinom getestet werden [24,64]. Es besteht auch weiterhin ein kontinuierliches Interesse an Fluoropyrimidine innerhalb von Studien, in denen die Effektivität von 5-FU nach venöser Applikation und durch Entwicklung oral zu verabreichender Chemotherapeutika verbessert werden soll [24,64] [39]. In dem mit Kombinationstherapie behandelten Studienarm wurde eine deutlich höhere Toxizität (51%) im Vergleich zur alleinigen 5-FU-Therapie (27%) beobachtet [39].…”

Section: Onkologische Therapien Beim Fortgeschrittenen Pankreaskarzinomunclassified

“…5-FU zusammen mit Cisplatin als Radiosensitiser und anschließend fortgesetzter Leucovorin-Therapie bewirkte hingegen ein medianes Über-leben von 7,7 bzw. 9 Monaten [24,64].…”

Section: Onkologische Therapien Beim Fortgeschrittenen Pankreaskarzinomunclassified

“…Aufgrund der schweren Toxizität kann dieses Regimen jedoch nicht als Routinetherapie empfohlen werden [24,64]. Durch eine alleinige oder kombinierte intraoperative Radiotherapie (IORT) oder Brachytherapie wird ebenfalls kein Benefit für den Patienten erzielt [24,64]. Obwohl die aktuellsten Studien nach CRT ein akzeptables Über-leben schildern, sind die Ergebnisse im Vergleich zur alleinigen Chemotherapie nicht überzeugend besser.…”

Section: Onkologische Therapien Beim Fortgeschrittenen Pankreaskarzinomunclassified

See 2 more Smart Citations

Adjuvante und additive Therapie beim Pankreaskarzinom

Neoptolemos

Raraty

Ghaneh

et al. 2003

Chirurg

View full text Add to dashboard Cite

Recent advances have been made in the treatment of pancreas cancer. Specialized pancreas centres have reported an increasing rate of resections with reduced postoperative mortality. On account of the highly aggressive nature of pancreas cancer, there is a great challenge in identifying effective therapy concepts for advanced stages of the cancer as well as for the development of resection-associated measures. As large-scale, randomised, controlled studies are lacking, the additive therapy concepts after resection do not have a sufficiently scientific basis. The ESPAC-1 study, which included 600 patients, surpassed all previous studies on adjuvant therapy for pancreas cancer. This study has shown,for example, that the most promising adjuvant chemotherapy with 5-fluorouracil and folic acid leads to an equal if not better result than the multimodal regimen. This regimen can be superseded with the use of Gemcitabine, which will be evaluated in the ESPAC-3 study that includes 990 patients from various European countries including Germany, as well as from Canada and Australia. Participation in the large, phase-3 study therefore plays a key role in the continued development of the management of pancreas cancer.

show abstract